Compare HTZ & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTZ | ANL |
|---|---|---|
| Founded | 1918 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 669.4M | 611.1M |
| IPO Year | 2021 | 2022 |
| Metric | HTZ | ANL |
|---|---|---|
| Price | $2.33 | $12.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.67 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 40.8M | 200.8K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,504,000,000.00 | N/A |
| Revenue This Year | $4.94 | $36.02 |
| Revenue Next Year | $3.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.45 | $0.88 |
| 52 Week High | $8.18 | $17.25 |
| Indicator | HTZ | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 53.18 |
| Support Level | $1.58 | $12.41 |
| Resistance Level | $5.50 | $13.29 |
| Average True Range (ATR) | 0.32 | 1.06 |
| MACD | 0.18 | -0.05 |
| Stochastic Oscillator | 57.86 | 38.40 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.